Engineering designer beta cells with a CRISPR-Cas9 conjugation platform

Donghyun Lim; Vedagopuram Sreekanth; Kurt J. Cox; Benjamin K. Law; Bridget K. Wagner; Jeffrey M. Karp; Amit Choudhary

doi:10.1038/s41467-020-17725-0

Nature Communications (Aug 2020)

Engineering designer beta cells with a CRISPR-Cas9 conjugation platform

Donghyun Lim,
Vedagopuram Sreekanth,
Kurt J. Cox,
Benjamin K. Law,
Bridget K. Wagner,
Jeffrey M. Karp,
Amit Choudhary

Affiliations

Donghyun Lim: Chemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard
Vedagopuram Sreekanth: Chemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard
Kurt J. Cox: Chemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard
Benjamin K. Law: Chemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard
Bridget K. Wagner: Chemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard
Jeffrey M. Karp: Engineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women’s Hospital, Harvard Medical School
Amit Choudhary: Chemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard

DOI: https://doi.org/10.1038/s41467-020-17725-0
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 11

Abstract

Read online

Cas9 fusions partners are often limited to natural polypeptide chains at the Cas9 termni. Here the authors present a platform for site-specific and multiple-site conjugation to both termini and internal sites of Cas9, and they apply this platform to efficiently engineer insulin-producing β cells.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal